

Japan offers new treatment option for brain cancer

02 November 2021 | News

Daiichi Sankyo launches DELYTACT® Oncolytic Virus G47? in Japan



Japanese firm Daiichi Sankyo Company has launched DELYTACT® (teserpaturev/G47?), an oncolytic virus developed by the company in collaboration with Professor Tomoki Todo of the Institute of Medical Science, The University of Tokyo.

DELYTACT® (teserpaturev/G47?) is a genetically engineered oncolytic herpes simplex virus type 1 (HSV-1).

DELYTACT® received conditional and time-limited marketing approval in Japan as a regenerative medical product for treatment of malignant glioma in June 2021 based on results from a Japanese phase 2 clinical trial (investigator-initiated trial) in patients with glioblastoma (a type of malignant glioma) conducted by Dr. Todo.

For the time being, DELYTACT® will be commercially available only at hospitals that served as trial sites. Daiichi Sankyo will establish a stable supply system of the medicine as soon as possible.

Daiichi Sankyo is offering DELYTACT® as a new option for the treatment of malignant glioma and to contribute to the high unmet medical needs of patients suffering from this brain cancer.